The Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2-Breast Cancer: A Multicenter Observational Study from Turkey

Sadeleştirilmiş öğe sayfası
dc.contributor.authorMuglu, Harun
dc.contributor.authorHelvaci, Kaan
dc.contributor.authorKoylu, Bahadir
dc.contributor.authorYucel, Mehmet Haluk
dc.contributor.authorCelayir, Ozde Melisa
dc.contributor.authorDemirci, Umut
dc.contributor.authorUluc, Basak Oyan
dc.contributor.authorBasaran, Gul
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorSelcukbiricik, Fatih
dc.contributor.authorOlmez, Omer Fatih
dc.contributor.authorBilici, Ahmet
dc.date.accessioned2025-10-16T15:11:48Z
dc.date.issued2025
dc.identifier.doi10.3390/cancers17091592
dc.identifier.otherWOS:001486131800001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/5021
dc.publisherMDPI
dc.sourceCANCERS
dc.subjectsacituzumab govitecan
dc.subjectreal\\-world data
dc.subjectmetastatic breast cancer
dc.subjecttriple\\-negative breast cancer
dc.subjecthormone receptor\\-positive breast cancer
dc.subjectTrop\\-2
dc.subjectantibody\\-drug conjugate
dc.titleThe Clinical Outcomes and Safety of Sacituzumab Govitecan in Heavily Pretreated Metastatic Triple-Negative and HR+/HER2-Breast Cancer: A Multicenter Observational Study from Turkey
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS